SELUTION持续释放西罗莫司药物涂层球囊治疗股腘动脉病变的首个人体单臂试验6个月结果
SELUTION SLR首次人体单臂试验在4家德国中心纳入50例有症状股腘动脉病变患者,6个月造影晚期管腔丢失均数0.29±0.84 mm,显著低于非涂层球囊的客观性能标准1.04 mm(p<0.001),原发性通畅率88.4%,无造影二元再狭窄率91.2%,仅1例(2%)发生临床驱动的靶病变血运重建,无其他主要不良事件。
要点
- 6个月造影晚期管腔丢失均数0.29±0.84 mm,显著低于非涂层球囊OPC值1.04 mm。
- 双功超声原发性通畅率88.4%,无造影二元再狭窄率91.2%。
- 仅1例(2%)发生临床驱动靶病变血运重建,无其他主要不良事件。
核心结论
- SELUTION SLR药物涂层球囊在6个月时能有效且安全地抑制再狭窄,改善有症状股腘动脉病变患者的结局。
研究设计与样本
- SELUTION SLR首次人体单臂试验(NCT02941224),2016年10月至2017年5月在4家德国中心纳入50例有症状中重度下肢缺血(Rutherford 2或3级)患者,平均年龄69.6±10.4岁,男性29例。
- 主要目标为比较6个月造影晚期管腔丢失与非涂层球囊客观性能标准值1.04 mm。
主要发现
- 6个月造影晚期管腔丢失中位数0.19 mm(范围-1.16至3.07),均数(n=34)0.29±0.84 mm(95%CI -0.01至0.58),显著低于1.04 mm的OPC值(p<0.001)。
- 双功超声原发性通畅率88.4%,无造影二元再狭窄率91.2%。
- 6个月内Rutherford分级(p<0.001)和ABI测量(p<0.001)较基线显著改善。
- 5个月时发生1例(2%)临床驱动靶病变血运重建,无其他主要不良事件。
关键数值与推荐
- 主要终点对比的OPC值为非涂层球囊血管成形术的1.04 mm。
- 主要不良事件复合终点包括心血管死亡、指数肢体截肢、靶肢体血栓形成和临床驱动靶病变血运重建。
临床怎么用
- SELUTION SLR药物涂层球囊可作为有症状股腘动脉病变的候选治疗选择,6个月随访显示再狭窄抑制有效且安全性良好。
- 需注意该结果来自首个人体单臂试验,尚需更大规模对照研究验证。
局限性
- 单臂设计,无同期对照组,主要终点为与历史OPC值比较。
- 样本量50例,6个月造影晚期管腔丢失可评估者仅34例。
- 随访时间仅6个月,缺乏长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To evaluate the safety and efficacy of the novel SELUTION sustained-limus-release (SLR) drug-eluting balloon (DEB) in the treatment of femoropopliteal lesions. Materials and Methods: Between October 2016 and May 2017, 50 subjects (mean age 69.6±10.4 years; 29 men) with symptomatic moderate to severe lower limb ischemia (Rutherford categories 2 or 3) were enrolled at 4 German centers for the SELUTION SLR first-in-human trial (ClinicalTrials.gov NCT02941224). The SELUTION SLR utilizes micro-reservoirs (biodegradable polymer spheres containing sirolimus) embedded within an amphipathic membrane coated onto an angioplasty balloon. The biodegradable reservoirs are transferred to the target vessel lumen during brief balloon inflation. The primary trial objective was comparison of angiographic late lumen loss at 6 months against an objective performance criterion (OPC) value of 1.04 mm for uncoated balloon angioplasty. Secondary endpoints included device, procedural, and clinical success; clinical and imaging assessments of primary patency and restenosis; functional assessments including Rutherford category and ankle-brachial index (ABI); and major adverse events [composite of cardiovascular mortality, index limb amputation, target limb thrombosis, and clinically-driven target lesion revascularization (CD-TLR)]. Results: At 6 months, median angiographic late lumen loss following SELUTION SLR treatment was 0.19 mm (range -1.16 to 3.07). Mean angiographic late lumen loss (n=34) was 0.29±0.84 mm (95% CI -0.01 to 0.58), significantly lower than the 1.04-mm OPC value (p<0.001). The rate of primary patency by duplex ultrasound was 88.4%, and freedom from angiographic binary restenosis was 91.2%. Through 6 months, there was significant improvement over baseline in Rutherford categories (p<0.001) and in ABI measurements (p<0.001). A single case (2%) of CD-TLR occurred at 5 months. There were no other major adverse events. Conclusion: Through 6 months, the SELUTION SLR DEB appears to inhibit restenosis effectively and safely, improving outcomes in subjects with symptomatic femoropopliteal disease.
引用
- Zeller T, Brechtel K, Meyer DR, et al. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions. J Endovasc Ther. 2020. PMID: 32666871. doi:10.1177/1526602820941811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。